Of note, Trastuzumab-deruxtecan, an antibody–drug conjugate with unprecedent efficacy in advance disease patients (DX-8951 derivative, DXd) [45, 46] has been shown to enhance anti-tumor immunity by promoting CXCL9/10 production by targeted tumor cells, increasing the number of tumor-infiltrating CD8+ T cells in preclinical models [47]. Here, CD8A is linked to neoplasm.